PROTAC P9, developed by Miao et al. [46] in 2023, degraded SHP-2 with a DC50 of 35.2 ± 1.5 nM and showed remarkable in vivo efficacy with almost complete tumor regression in a KYSE520 esophageal cancer xenograft mouse model while being well tolerated over 18 days (Figure 2). This evidence concerns the gene PTPN11 and esophageal cancer.